Efficacy and Safety of Alogliptin in Patients With Type 2 Diabetes: Analysis of the ATTAK-J Study

BACKGROUND: Dipeptidyl peptidase-4 (DPP-4) inhibitors have been shown to reduce hemoglobin A1c (HbA1c) in patients with type 2 diabetes, but the reduction varies between patients and adequate glycemic control may not be achieved. We evaluated the efficacy and safety of the DPP-4 inhibitor alogliptin...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeda, Hiroshi, Sasai, Nobuo, Ito, Shogo, Obana, Mitsuo, Takuma, Tetsuo, Takai, Masahiko, Kaneshige, Hideaki, Machimura, Hideo, Kanamori, Akira, Nakajima, Kazumi, Matsuba, Ikuro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4701069/
https://www.ncbi.nlm.nih.gov/pubmed/26767082
http://dx.doi.org/10.14740/jocmr2418w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4701069/
https://www.ncbi.nlm.nih.gov/pubmed/26767082
http://dx.doi.org/10.14740/jocmr2418w

Ejemplares similares